Alzheimer's Research & Therapy invites submissions for a thematic series focusing on the use of artificial intelligence, machine learning and related techniques in dementia research.
Find out more about the series and how to submit here.
Call for Papers - AI in Dementia
Announcing the launch of In Review
In partnership with Research Square, Alzheimer's Research & Therapy is now offering In Review. Authors choosing this free optional service will be able to:
- Share their work with fellow researchers to read, comment on, and cite even before publication
- Showcase their work to funders and others with a citable DOI while it is still under review
- Track their manuscript - including seeing when reviewers are invited, and when reports are received
Read more about the full range of benefits of In Review and how to opt in, or see the In Review platform for yourself here.
Articles
-
-
Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimer’s disease: findings from the Colombia-Boston (COLBOS) biomarker study
-
Assessing individual-level change in dementia research: a review of methodologies
-
AlzGPS: a genome-wide positioning systems platform to catalyze multi-omics for Alzheimer’s drug discovery
-
An MRI-based strategy for differentiation of frontotemporal dementia and Alzheimer’s disease
-
Stem cell factor and granulocyte colony-stimulating factor reduce β-amyloid deposits in the brains of APP/PS1 transgenic mice
-
BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
-
Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
-
Cerebral microbleeds: overview and implications in cognitive impairment
-
Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice?
Early Career Researcher Reviewer Panel
Interested in an introduction to peer reviewing articles for Alzheimer's Research & Therapy?
Find out more about our ECR Peer Reviewer Panel!
Aims and scope
Alzheimer's Research & Therapy is the major forum for translational research into Alzheimer's disease. An international peer-reviewed journal, it publishes open access basic research with a translational focus, as well as clinical trials, research into drug discovery and development, and epidemiologic studies. The journal also provides reviews, viewpoints, commentaries, debates and reports.
Although the primary focus is Alzheimer's disease, the scope encompasses translational research into other neurodegenerative diseases.
Published Thematic Series
Alzheimer's blogs from BMC
-
-
World Alzheimer’s Month: Let’s talk about dementia to end the stigma
20 September 2019
-
Spotlight on Alzheimer’s Research: Brain Awareness Week 2019
27 February 2019
Affiliated with
Annual Journal Metrics
-
Speed
56 days to first decision for reviewed manuscripts only
32 days to first decision for all manuscripts
128 days from submission to acceptance
25 days from acceptance to publication
Citation Impact
6.116 - 2-year Impact Factor
7.114 - 5-year Impact Factor
1.546 - Source Normalized Impact per Paper (SNIP)
2.298 - SCImago Journal Rank (SJR)
Usage
657,918 downloads
1,172 Altmetric mentions
